Profile: Merck & Co Inc (MRK)
2 Dec 2016
Merck & Co., Inc., incorporated on 1970, is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products, which it markets directly and through its joint ventures. It operates through one segment, Pharmaceutical. The Company's Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures. The Company has operations in Pharmaceutical, Animal Health, Alliances and Healthcare Services segments. Human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. The Company sells its human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed healthcare providers, such as health maintenance organizations, pharmacy benefit managers and other institutions. Vaccine products consist of preventive pediatric, adolescent and adult vaccines, primarily administered at physician offices.
The Company sells its human health vaccines primarily to physicians, wholesalers, physician distributors and government entities. The Animal Health segment discovers, develops, manufactures and markets animal health products, including vaccines. The Company's animal health products are sold to veterinarians, distributors and animal producers. The Company's Animal Health segment includes pharmaceutical and vaccine products for the prevention, treatment and control of disease in various farm and companion animal species. The Company's Healthcare Services segment provides services and solutions that focus on engagement, health analytics and clinical services. The Company's clinical pipeline includes candidates in multiple disease areas, including atherosclerosis, cancer, cardiovascular diseases, diabetes, infectious diseases, inflammatory/autoimmune diseases, neurodegenerative diseases, osteoporosis, respiratory diseases and women's health.
The Company's products under Phase II include MK-7622, which is indicated for Alzheimer's Disease; MK-1029, which is indicated for asthma; MK-3475 Keytruda, which is treated for hodgkin lymphoma primary mediastinal large B-cell lymphoma (PMBCL) advanced solid tumors, MK-2206 and MK-8628, which are indicated for cancer; MK-8521, which is indicated for diabetes; MK-1242 (vericiguat), which is indicated for Heart Failure; MK-3682B (MK-3682/MK-8408/MK-5172 (grazoprevir)), which is indicated for Hepatitis C, and V114, which is indicated for pneumoconjugate vaccine. Its products under Phase III include MK-8237, House Dust Mite for Allergy; MK-8931 (verubecestat) for Alzheimer's Disease; MK-0859 (anacetrapib) for Atherosclerosis; MK-7655A (relebactam+imipenem/cilastatin) for Bacterial Infection; MK-3475 Keytruda for various cancers, such as Bladder, Breast, Colorectal, Esophageal, Gastric, Head and Neck, and multiple Myeloma; MK-8228 (letermovir) for cytomegalovirus (CMV) prophylaxis in transplant patients; MK-8342B for contraception, next generation ring; MK-3102 (omarigliptin), MK-8835 (ertugliflozin), MK-8835A (ertugliflozin+sitagliptin), MK-8835B (ertugliflozin+metformin), MK-1293 and MK-0431J (sitagliptin+ipragliflozin) are indicated for Diabetes Mellitus; V920 for Ebola Vaccine; V212 (inactivated VZV vaccine) for Herpes Zoster; MK-1439 (doravirine) for human immunodeficiency virus (HIV), and MK-0822 (odanacatib) for osteoporosis. The Company's products under review include MK-3475 Keytruda non-small-cell lung for cancer; MK-6072 (bezlotoxumab) for clostridium difficile infection; MK-1293 for diabetes mellitus; MK-5172A Zepatier for Hepatitis C and V419 for pediatric hexavalent combination vaccine.
The Company's pharmaceutical products include therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. The Company provides products in various divisions, such as Primary Care and Women's Health, Hospital and Specialty, Oncology, Diversified Brands and Vaccines. The Company's Primary Care and Women's Health division offers products of different therapeutic segments, such as Cardiovascular, which include Zetia (ezetimibe) (marketed as Ezetrol outside the United States) and Vytorin (ezetimibe/simvastatin) (marketed as Inegy outside the United States), cholesterol modifying medicines; Diabetes, which includes Januvia (sitagliptin) and Janumet (sitagliptin/metformin HCl) for the treatment of type 2 diabetes; General Medicine and Women's Health, which includes NuvaRing (etonogestrel/ethinyl estradiol vaginal ring) that is a vaginal contraceptive product, Implanon (etonogestrel implant) that is a single-rod subdermal contraceptive implant/Nexplanon (etonogestrel implant), a single, radiopaque, rod-shaped subdermal contraceptive implant, Dulera Inhalation Aerosol (mometasone furoate/formoterol fumarate dihydrate), a combination medicine for the treatment of asthma, and Follistim AQ (follitropin beta injection) (marketed as Puregon in most countries outside the United States), a fertility treatment.
The Company's Hospital and Specialty division offers products under various therapeutic categories, such as Hepatitis, which includes PegIntron (peginterferon alpha-2b) and Victrelis (boceprevir), medicines for the treatment of hepatitis C virus (HCV); HIV, which include Isentress (raltegravir), an HIV integrase inhibitor for use in combination with other antiretroviral agents for the treatment of HIV-1 infection, and Acute Care, which includes Cancidas (caspofungin acetate), an anti-fungal product; Invanz (ertapenem sodium) for the treatment of certain infections, Noxafil (posaconazole) for the prevention of invasive fungal infections, Bridion (sugammadex) Injection, a medication for the reversal of two types of neuromuscular blocking agents used during surgery, Primaxin (imipenem and cilastatin sodium), an anti-bacterial product, Cubicin (daptomycin for injection), an intra-venous (I.V.) antibiotic for complicated skin and skin structure infections or bacteremia, when caused by designated susceptible organisms, and Zerbaxa (ceftolozane/tazobactam), an I.V. combination product for the treatment of complicated intra-abdominal infections or complicated urinary tract infections, when caused by designated susceptible organisms. Its Hospital and Specialty division also offers products under therapeutic categories, including Immunology, which includes Remicade (infliximab), a treatment for inflammatory diseases, and Simponi (golimumab), a once-monthly subcutaneous treatment of certain inflammatory diseases, which the Company markets in Europe, Russia and Turkey, and Other category, which includes Cosopt (dorzolamide hydrochloride-timolol maleate ophthalmic solution), which the Company markets outside the United States, and Trusopt (dorzolamide hydrochloride ophthalmic solution), ophthalmic products.
The Company's Oncology division offers products, which includes Emend (aprepitant) for the prevention of chemotherapy-induced and post-operative nausea and vomiting; Temodar (temozolomide) (marketed as Temodal outside the United States), a treatment for certain types of brain tumors; and Keytruda (pembrolizumab) for the treatment of advanced melanoma in patients whose disease has progressed after other therapies. The Company's Diversified Brands division offers products under various therapeutic categories, such as Respiratory, which includes Nasonex (mometasone furoate monohydrate), an inhaled nasal corticosteroid for the treatment of nasal allergy symptoms, Singulair (montelukast), a medicine indicated for the chronic treatment of asthma and the relief of symptoms of allergic rhinitis and Clarinex (desloratadine), a non-sedating antihistamine, and Other, which includes Cozaar (losartan potassium) and Hyzaar (losartan potassium and hydrochlorothiazide), treatments for hypertension; Arcoxia (etoricoxib) for the treatment of arthritis and pain, which the Company markets outside the United States; Fosamax (alendronate sodium) (marketed as Fosamac in Japan) for the treatment and prevention of osteoporosis; Propecia (finasteride), a product for the treatment of male pattern hair loss; Zocor(simvastatin), a statin for modifying cholesterol; and Remeron (mirtazapine), an antidepressant. The Company's Vaccines division includes products, such as Gardasil (Human Papillomavirus Quadrivalent [Types 6, 11, 16 and 18] Vaccine, Recombinant), a vaccine to help prevent certain diseases caused by four types of human papillomavirus (HPV); ProQuad (Measles, Mumps, Rubella and Varicella Virus Vaccine Live), a pediatric combination vaccine to help protect against measles, mumps, rubella and varicella; M-M-R II (Measles, Mumps and Rubella Virus Vaccine Live), a vaccine to help prevent measles, mumps and rubella; Varivax (Varicella Virus Vaccine Live), a vaccine to help prevent chickenpox (varicella); Zostavax (Zoster Vaccine Live), a vaccine to help prevent shingles (herpes zoster); Pneumovax 23 (pneumococcal vaccine polyvalent), a vaccine to help prevent pneumococcal disease, and RotaTeq (Rotavirus Vaccine, Live Oral, Pentavalent), a vaccine to help protect against rotavirus gastroenteritis in infants and children.
The Animal Health segment discovers, develops, manufactures and markets animal health products, including vaccines. The principal products in this segment include Livestock Products, Poultry Products, Companion Animal Products, and Aquaculture Products. Livestock Products, includes Nuflor antibiotic range for use in cattle and swine; Bovilis/Vista vaccine lines for infectious diseases in cattle; Banamine bovine and swine anti-inflammatory; Estrumate for the treatment of fertility disorders in cattle; Regumate/Matrix fertility management for swine and horses; Resflor, a combination broad-spectrum antibiotic and non-steroidal anti-inflammatory drug for bovine respiratory disease; Zuprevo for bovine respiratory disease; Zilmax and Revalor to improve production efficiencies in beef cattle; M+Pac swine pneumonia vaccine, and Porcilis vaccine line for infectious diseases in swine. Its Poultry Products include Nobilis/Innovax, vaccine lines for poultry and Paracox and Coccivac coccidiosis vaccines. Its Companion Animal Products include Nobivac vaccine lines for flexible dog and cat vaccination; Otomax/Mometamax/Posatex ear ointments for acute and chronic otitis; Caninsulin/Vetsulin diabetes mellitus treatment for dogs and cats; Panacur/Safeguard broad-spectrum anthelmintic (de-wormer) for use in many animals; Activyl/Scalibor/Exspot for protecting against bites from fleas, ticks, mosquitoes and sandflies; and Bravecto (fluralaner), a chewable tablet that kills fleas and ticks in dogs for over 12 weeks. Its Aquaculture Products include Slice parasiticide for sea lice in salmon; Aquavac/Norvax vaccines against bacterial and viral disease in fish; Compact PD vaccine for salmon, and Aquaflor antibiotic for farm-raised fish.
Merck & Co Inc
2000 Galloping Hill Rd
KENILWORTH NJ 07033-1310
Company Web Links
- Merck wins UK okay for Keytruda in lung cancer after price cut
- BRIEF-FDA grants priority review to Merck's supplemental biologics license application (SBLA) for Keytruda
- Gilead, Merck to face off before jury over hepatitis C drug patents
- BRIEF-Merck raises quarterly dividend to $0.47/share from $0.46/share
- Gilead loses bid to invalidate two Merck hepatitis C patents ahead of trial